ES2031890T3 - Un procedimiento para preparar nuevos derivados amino-dihidrooxazoles,-tiazolels e -imidazoles sustituidos. . - Google Patents

Un procedimiento para preparar nuevos derivados amino-dihidrooxazoles,-tiazolels e -imidazoles sustituidos. .

Info

Publication number
ES2031890T3
ES2031890T3 ES198787304019T ES87304019T ES2031890T3 ES 2031890 T3 ES2031890 T3 ES 2031890T3 ES 198787304019 T ES198787304019 T ES 198787304019T ES 87304019 T ES87304019 T ES 87304019T ES 2031890 T3 ES2031890 T3 ES 2031890T3
Authority
ES
Spain
Prior art keywords
procedure
tiazolels
dihydrooxazole
substitutes
imidazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787304019T
Other languages
English (en)
Inventor
Lee James Beecham Pharmaceuticals Beeley
John Beecham Pharmaceuticals Berge
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Application granted granted Critical
Publication of ES2031890T3 publication Critical patent/ES2031890T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/28—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

UN COMPUESTO DE FORMULA (I) O UNA SAL FARMACOLOGICAMENTE ACEPTABLE OBTENIDA POR ADICION DE ACIDO Y/O UN SOLVATO FARMACOLOGICAMENTE ACEPTABLE DEL MISMO, DONDE R1 Y R2 REPRESENTA CADA UNO INDEPENDIENTEMENTE UN ATOMO DE HIDROGENO O DE HALOGENO, UN GRUPO ALQUILO DE C1 A C6 O UN GRUPO ALCOXI DE C1 A C6; R3 Y R4 REPRESENTAN CADA UNO INDEPENDIENTEMENTE UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO DE C1 A C6; X REPRESENTA UN ENLACE O UNA MITAD DE CHR5 DONDE R5 ES UN GRUPO R3; Y Z REPRESENTA O O NH. UN PROCEDIMIENTO PARA PREPARAR DICHOS COMPUESTOS, UNA COMPOSICION FARMACOLOGICA QUE LOS CONTIENE Y EL USO DICHOS COMPUESTOS Y COMPOSICIONES EN MEDICINA.
ES198787304019T 1986-05-03 1987-05-05 Un procedimiento para preparar nuevos derivados amino-dihidrooxazoles,-tiazolels e -imidazoles sustituidos. . Expired - Lifetime ES2031890T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868610909A GB8610909D0 (en) 1986-05-03 1986-05-03 Compounds

Publications (1)

Publication Number Publication Date
ES2031890T3 true ES2031890T3 (es) 1993-01-01

Family

ID=10597340

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787304019T Expired - Lifetime ES2031890T3 (es) 1986-05-03 1987-05-05 Un procedimiento para preparar nuevos derivados amino-dihidrooxazoles,-tiazolels e -imidazoles sustituidos. .

Country Status (12)

Country Link
US (1) US4861789A (es)
EP (1) EP0251453B1 (es)
JP (1) JPS62267270A (es)
AU (1) AU600939B2 (es)
DE (1) DE3767789D1 (es)
DK (1) DK227487A (es)
ES (1) ES2031890T3 (es)
GB (1) GB8610909D0 (es)
GR (1) GR3001416T3 (es)
NZ (1) NZ220179A (es)
PT (1) PT84818B (es)
ZA (1) ZA873169B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034406A (en) * 1989-09-26 1991-07-23 Allergan, Inc. Method for reducing or maintaining intraocular pressure
US5066664A (en) * 1990-02-28 1991-11-19 Allergan, Inc. 2-(hydroxy-2-alkylphenylamino)-oxazolines and thiazolines as anti-glaucoma and vasoconstrictive agents
DK148292D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Forbindelser
US5580892A (en) * 1993-10-22 1996-12-03 Allergan Method for using 2-(2-alkylphenylamino)-oxazolines as adrenergic agents
JPH10502643A (ja) * 1994-07-11 1998-03-10 アラーガン α▲下２▼アドレナリン遮断剤として有用な、立体配座の定まった二環およびアダマンタン誘導体
US6150389A (en) 1994-07-11 2000-11-21 Allergan Sales, Inc. Comformationally rigid bicyclic and adamantane derivatives useful as α2 -adrenergic blocking agents
DE19514579A1 (de) * 1995-04-20 1996-10-24 Boehringer Ingelheim Kg Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
EP1986498A2 (en) 2006-02-15 2008-11-05 Bayer CropScience AG Insecticidal substituted amino heterocyclic and heteroaryl derivatives
EP1988080A1 (en) * 2007-05-03 2008-11-05 Bayer CropScience AG Insecticidal substituted 2-aminoindanes
WO2008145615A2 (en) * 2007-05-25 2008-12-04 Basf Se Aminoazoline and urea derivatives for combating animal pests
CA2696404A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Therapeutic compounds
WO2009023752A1 (en) * 2007-08-15 2009-02-19 Allergan, Inc. Adrenergic compounds
KR20100071990A (ko) * 2007-08-15 2010-06-29 알러간, 인코포레이티드 녹내장 및 통증과 같은 질환의 처치에 유용한 헤테로사이클 치환된 융합 카르보사이클
BRPI0906925A2 (pt) * 2008-01-18 2019-09-24 Allergan Inc agentes adrenérgicos do subtipo alfa 2 seletivos e métodos de uso dos mesmos

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2883410A (en) * 1957-07-08 1959-04-21 Pfizer & Co C N-(1-indanyl)-n'-(beta-substituted ethyl)-ureas
US2870161A (en) * 1957-07-08 1959-01-20 Pfizer & Co C 2-(1-indanyl amino)-oxazolines
US2870159A (en) * 1957-07-08 1959-01-20 Pfizer & Co C Hydrogenated 2-(1-naphthylamino)-oxazolines
DE1195323B (de) * 1963-06-24 1965-06-24 Thomae Gmbh Dr K Verfahren zur Herstellung von 2-[5', 6', 7', 8'-Tetrahydronaphthyl-(1')-amino]-imidazolin und seinen Salzen
US3432600A (en) * 1963-09-30 1969-03-11 Du Pont Partially reduced 2-(1-napthylamino) oxazoline,indanylethylureas,and indanylaminooxazoline
US3679798A (en) * 1964-02-28 1972-07-25 Du Pont Composition comprising arylaminooxazoline and antichloligeneric agent
DE1670751A1 (de) * 1966-09-27 1970-12-23 Bayer Ag Verfahren zur Herstellung von 2-Phenylamino-2-oxazolinen
DE1670753A1 (de) * 1966-09-27 1970-07-16 Bayer Ag Verfahren zur Herstellung von 2-Cycloalkylaminooxazolinen
US3882229A (en) * 1972-07-21 1975-05-06 Nordmark Werke Gmbh Composition and method for shrinking mucous membranes
JPS54151990A (en) * 1978-04-17 1979-11-29 Beiersdorf Ag Novel condensated nitrogenncontained heterocyclic compound and its manufacture

Also Published As

Publication number Publication date
GB8610909D0 (en) 1986-06-11
PT84818A (en) 1987-06-01
US4861789A (en) 1989-08-29
AU7247987A (en) 1987-11-05
DE3767789D1 (de) 1991-03-07
NZ220179A (en) 1989-10-27
GR3001416T3 (en) 1992-09-25
DK227487A (da) 1987-11-04
EP0251453A2 (en) 1988-01-07
ZA873169B (en) 1988-04-27
AU600939B2 (en) 1990-08-30
JPS62267270A (ja) 1987-11-19
EP0251453A3 (en) 1988-09-28
EP0251453B1 (en) 1991-01-30
PT84818B (pt) 1989-12-29
DK227487D0 (da) 1987-05-04

Similar Documents

Publication Publication Date Title
ES2031890T3 (es) Un procedimiento para preparar nuevos derivados amino-dihidrooxazoles,-tiazolels e -imidazoles sustituidos. .
ES2067456T3 (es) Nuevos derivados de aminoacidos, procedimientos para su preparacion y composicion farmaceutica que los comprende.
AR245705A1 (es) Un proceso para preparar leucotrienos-antagonistas y sus sales.
DK57281A (da) Fremgangsmaade til fremstilling af substituerede imidazolderivater eller syreadditionssalte deraf
ES433902A1 (es) Procedimiento para la preparacion de bencilaminas.
ES2038630T3 (es) Un procedimiento para preparar un compuesto de acido fenoxiacetico.
NO812355L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3,1-benzoksazin-2-on-derivater
ES2053755T3 (es) Un procedimiento para preparar compuestos heterociclicos.
NO166321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinforbindelser.
ES518613A0 (es) Un procedimiento para preparar compuestos de acido quinolilacetico
ATE70838T1 (de) Substituierte 3-aminosydnonimine, verfahren zu ihrer herstellung und ihre verwendung.
ES8704459A1 (es) Procedimiento para la obtencion de acemetacina.
DK183082A (da) Fremgangsmaade til fremstilling af dioxaheterocycliske forbindelser eller salte deraf
PT77728B (en) Process for preparing acridanone derivatives and of pharmaceutical compositions containing the same
SE8701524D0 (sv) Nya sulfonamider och deras framstellningsforfarande
GB995398A (en) Novel hypotensive composition

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 251453

Country of ref document: ES